Диссертация (Факторы, влияющие на эффективность лечения внепеченочных поражений, ассоциированных с HCV – криоглобулинемией), страница 27

Viral Hepat. - 2000. – v.7. –p.23-29.156. Rossi P., Bertani T., Baio P. et al. Hepatitis C virus related cryoglobulinemic glomerulonephritis: longterm remission after antiviral therapy. // Kydney Int. – 2003. – v.63. p.2236-2241157. Saadoun D., Suarez F., Lefrere F. et al. Splenic lymphoma with villous lymphocytes? Associated withtype II cryoglobulinemia and HCV infection: a new entity? // Blood. – 2005. – v.105. – p.74-76158. Saadoun D., Resche-Rigon M., Thibault V. Antiviral therapy for hepatitis C virus– associated mixedcryoglobulinemia vasculitis: A long-term followup study. // Arthritis Rheum.

– 2006. –v.54. – p.36963706.159. Saadom D., Landau D.A. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad betweenautoimmunity and lymphoproliferation. // Rheumatology. – 2007. – v.46. – p.1234-1242.160. Saadoun D., Resche-Rigon M., Sene D. et al. Rituximab combined with Peg-interferon- ribavirin inrefractory hepatitis C virus-associated cryoglobulinemia vasculitis.

// Ann Rheum Dis. – 2008. – v.67. –p.1431-1436.161. Saadoun D., Resche- Rigon M. Rituximab plus Peg-interferon-α/ribavirin compared with Peginterferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia. // Blood. - 2010. - v.116. - no.3. –p.326-334.162. Saadom D., Rosenzwajg M. Regulatory T-cell response to low-dose interleukin-2 in HCV-inducedvasculitis. // New England journal of medicine. – 2011. - v.365. - no 22. - р.2067- 2077.163.

Saadoun D., Resche Rigon M., Pol S., Thibault V., et al. PegIFNα/ribavirin/proteaseinhibitorcombination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. // J Hepatol.2015. - v.62. – p.24-30.164.Sansonno D., Lacobelli A.R., Cornacchiulo V. et al. Immunochemical andbiomolecular studies of circulating immune complexes isolated from patients with acute andchronic hepatitis С virus infection.

Eur. J. Clin. Invest. 1996, 26. 465 -475165. Sansonno D., De Re V., Lauletta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemiaresistant to interferon-a with an anti-CD20. // Blood. – 2003. – v.101. - 3818-3826.166. Schinazi R., Halfon P., Marcellin P., Asselah T. HCV direct-acting antiviral agents: the best interferonfree combinations. // Liver Int. – 2014. – v.34 (Suppl 1). – p.69-78.167.

Sene D., Ghilliani-Dalbin P., Thibault V. et al. Longterm course of mixed cryoglobulinemia in patientsinfected with hepatitis C virus. // J Rheumatol 2004. – v.31, - p.2199-2206168. Sène D., Limal N., Ghillani-Dalbin P., Saadoun D., et al. Hepatitis C virus-associated B- cellproliferation-the role of serum B lymphocyte stimulator (BLyS/BAFF).

// Rheumatology (Oxford). 2007. – v.46. – p.65-74.169. Sene D., Ghillani-Dalbin P., Amoura Z et al. Rituximab may form a complex with IgMkappa mixedcryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. //Arthritis Rheum. - 2009. – v.60. – p.3848-3855.170. Siagris D., Christofidou M., Tsamandas A., Lekkou A. Cryoglobulinemia and progression of fibrosis inchronic HCV infection: cause or effect? // J Infect.- 2004.- v.49. - p.236-277.171.

Sneller M.C., Hu Z., Langford C.A. A randomized controlled trial of rituximab following failure ofantiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. // Arthritis Rheum. – 2012.- v.64. – p.835-877.172. Stübgen J.P. Neuromuscular diseases associated with chronic hepatitis C virus infection. // J ClinNeuromuscul Dis. – 2011. – v.13.

– p.14-25.173. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoidtissues. Lyon: IARC Press. - 2008. – 439-450.174. Takada S., Shimizu T., Hadano Y. Cryoglobulinemia (review). // Mol Med Rep. – 2012. - v.6. – p.3-8.175. Tarantino A., Campise M., Banfi G., Confalonieri R., et al.

Long-term predictors of survival in essentialmixed cryoglobulinemic glomerulonephritis. // Kidney Int. – 1995. - v.47. – p.618-641.149176. Terrier B., Saadoun D., Sène D. Efficacy and tolerability of rituximab with or without PEGylatedinterferon alfa-2b plus ribavirin in severe hepatitis C virus–related vasculitis: long-term followup studyof thirty-two patients. // Arthritis Rheum. – 2009. - v.60.

– p.2531-2571.177. Terrier B., Semoun O., Saadoun D., Sène D. Prognostic factors in patients with hepatitis C virusinfection and systemic vasculitis. // Arthritis Rheum.- 2011.- v.63. - p.1748-1805.178. Terrier B., Cacoub P. Cryoglobulinemia vasculitis: an update. // Curr Opin Rheumatol.- 2013.- v.25.

–p.10-18.179. Terrier B., Karras A., Cluzel P. et al. Presentation and prognosis of cardiac involvement in hepatitis Cvirus-related vasculitis. 2013.- v.111.- p.265-272180. Tissot J.D., Schifferrli J.A., Hochstrasser D.F., et al. Two-dimensional poly-acrylamide gelelectroforesis analysis of cryoglobulins and identification of an IgM-associated peptide. // J ImmunolMeth.

– 1994. – v.173. – p.63-75.181. Tomoe M., Takatori M. Cryoglobulinemia associated with hepatitis C-related chronic liver disease inJapan. // Nihon Shokakibyo Gakkai Zasshi. – 1997. – v.94. – p.241-249.182. Toubi E., Gordon S., Kessel A., Rosner I. Elevated serum B-Lymphocyte activating factor (BAFF) inchronic hepatitis C virus infection: association with autoimmunity. // J Autoimmun. – 2006.

– v.27. –p.134-143.183. Trejo O., Ramos-Casals M., García-Carrasco M., Yagüe J., et al. Cryoglobulinemia: study of etiologicfactors and clinical and immunologic features in 443 patients from a single center. // Medicine(Baltimore). – 2001. - v.80. – p.252-314.184. Trejo O., Ramos-Casals M., Lopez-Guillermo A. et al.

Hematologic malignancies in patients withcryoglobolinemia: association with autoimmune and chronic viral diseases/ Semin Arthritis Rheum. 2003. – v.33. – p. 19-28185. Tursi A., Brandimarte G., Torello M. Disappearance of gastric mucosa-associated lymphoid tissue inhepatitis C virus therapy. // J Clin Gastroenterol. – 2004. – v.38. – p. 360-363186. Vallisa D., Berte R., Rocca A et al. Association between hepatitis C virus and non-Hodgkin’slymphoma and effects of viral infection on histologic subtype and clinical course.

// Am J Med. – 1999.– v.106.- p. 556-560187. Vallisa D., Bernuzzi P., Arcani L. et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related,low-grade? B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. // J Clin Oncol. – 2005. –v. 23. – p.468-473188. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F. A phase II, single-arm multicenter study of lowdose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.

//Autoimmun Rev.- 2011.- v.10. – p.714-723.189. Watson C.J. Studies of cryoglobulins. I. Unusual purpura associated with the presence of highconcentration of cryoglobulin (cold precipitable serum globulin). // Am J Med Sci.- 1947. – v.314. –p. 410-415.190. William E., St.Clair. Hepatitis C Virus-related cryoglobulinemic vasculitis: emerging trends in therapy.// Arthritis &rheumatism.- 2012. - v.64.- No 3. - p.604-608.191. Wink F., Houtman P.M., Jansen T.L.

Rituximab in cryoglobulinaemic vasculitis, evidence for itseffectivity: a case report and review of literature. // Clin Rheumatol. - 2011. – v.30. – p.293-300.192. Wintrobe M.M., Buell M.V. Hyperproteinemia associated with multiple myeloma. // Bull JohnHopkins Hosp. - 1933. – v.52.

– p.156-165.193. Zaja F., De Vita S., Mazzaro C. et al. Efficacy and safety ofrituximab in type II mixedcryoglobulinemia. // Blood. -2003. – v.101. – p.3827-3834194. Zignego A.L., Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease.//Intern Emerg Med.- 2012.- v.7(Suppl 3). – p.201-209.195. Zignego A.L., Giannini C., Gragnani L. HCV and Lymphoproliferation.

// Clin Dev Immunol. – 2012. –v.6. – p.43 - 49.